Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies (Q26825441)

Sangeeta B. Joshi

2

1 reference

Dawn E. Smith

3

1 reference

C. Russell Middaugh

4

1 reference

Ted Prusik

5

1 reference

David B. Volkin

6

1 reference

language of work or name

1 reference

September 2014

1 reference

1 reference

42

1 reference

PubMed

issue

5

1 reference

PubMed

page(s)

237-59

1 reference

Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Vaccine process technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Thermal stability of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Antimicrobial preservative use in parenteral products: past and present

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Vaccine adjuvants: current challenges and future approaches.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Multidimensional methods for the formulation of biopharmaceuticals and vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

The role of adjuvant in mediating antigen structure and stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Desirable attributes of vaccines for deployment in low-resource settings

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Elucidating mechanisms of thermostabilization of poliovirus by D2O and MgCl2

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Alternative routes of measles immunization: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Development of stable influenza vaccine powder formulations: challenges and possibilities

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Progress towards a needle-free hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Magnesium chloride enhancement of cell susceptibility to poliovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Parameters for plaque formation in the potency assay of Japanese measles vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Characterization of two differently glycosylated molecular species of yeast-derived hepatitis B vaccine carrying the pre-S2 region

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Elimination of serum proteins and potential virus contaminants during hepatitis B vaccine preparation

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Heat stability of a recombinant DNA hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Thermostabilization of live virus vaccines by heavy water (D2O).

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Efficacy of measles vaccine interlinked with potency and storage

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Current and future issues in the manufacturing and development of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Nanotechnology in vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Developments in the production and quality control of poliovirus vaccines -- historical perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Manufacturing and supply of monovalent oral polio vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Stability evaluation of vaccines: WHO approach.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Vaccine stability study design and analysis to support product licensure

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Maintenance of vaccine stability through annual stability and comparability studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Consideration on a few aspects of the stability studies post licensure

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Basic principles of stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Stability of vaccines - bridging from stability data to continuous safety and efficacy throughout shelf life - an always reliable approach?

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Goals of stability evaluation throughout the vaccine life cycle

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Guidelines on stability evaluation of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

WHO/KFDA workshop on stability evaluation of vaccines, Seoul, Korea, 23-25 April 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Stability evaluation of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Structural damages in adsorbed vaccines affected by freezing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

New adjuvants for human vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

The ABC of clinical and experimental adjuvants--a brief overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

HPV infections: can they be eradicated using nanotechnology?

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Clinical guidance on the use of live attenuated influenza vaccine after inadvertent freezing and warming.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Aluminium adjuvants--in retrospect and prospect

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

The virosome concept for influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter?

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

How many infective viral particles are necessary for successful mass measles immunization by aerosol?

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Freezing temperatures in the vaccine cold chain: a systematic literature review

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Characterization of a thermostable hepatitis B vaccine formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Heat-stable measles vaccine produced by spray drying

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Using oral polio vaccine beyond the cold chain: a feasibility study conducted during the national immunization campaign in Mali

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Preformulation studies--The next advance in aluminum adjuvant-containing vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Towards ambient temperature-stable vaccines: the identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Vaccine stabilization: research, commercialization, and potential impact

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Assessing the potency of oral polio vaccine kept outside of the cold chain during a national immunization campaign in Chad

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

The mechanism of action of MF59 - an innately attractive adjuvant formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Devices for intradermal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Exposure of hepatitis B vaccine to freezing temperatures during transport to rural health centers in Mongolia

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Live viral vaccine potency: an index for assessing the cold chain system

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Effect of vaccines on bacterial meningitis worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Recombinant polioviruses expressing hepatitis B virus-specific cytotoxic T-lymphocyte epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Capsid and RNA stabilisation of the oral polio vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Measles virus and immunomodulation: molecular bases and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Analysis of cationic-lipid-plasmid-DNA complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Development of a varicella virus vaccine stabilizer containing no animal-derived component

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Immunological mechanisms of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Efforts to improve vaccine stabilization heat up

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Toll-like receptor signalling

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Immunology of hepatitis B virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Influenza A viruses: new research developments

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Immunopathogenesis of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Influenza vaccines for the future

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

RETRACTED: Stabilization of vaccines and antibiotics in silk and eliminating the cold chain

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Development of a more thermostable poliovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Serious morbidity and mortality associated with influenza epidemics

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Six revolutions in vaccinology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Molecular tectonic model of virus structural transitions: the putative cell entry states of poliovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Hepatitis B virus biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Evaluation of the cold-chain for oral polio vaccine in a rural district of India

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Evaluation of an outside-the-cold-chain vaccine delivery strategy in remote regions of western China

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

TLR4 agonists as immunomodulatory agents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

A rational, systematic approach for the development of vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Cellular proteins in influenza virus particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Immunizations in the United States: success, structure, and stress

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

A review of multiple approaches towards an improved hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Tools and approaches to ensure quality of vaccines throughout the cold chain

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

New hepatitis B vaccine formulated with an improved adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Quality-control issues and approaches in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Role of heavy water in biological sciences with an emphasis on thermostabilization of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Opportunities and challenges of developing thermostable vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Vaccines as physically and chemically well-defined pharmaceutical dosage forms

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Influenza virosomes as a vaccine adjuvant and carrier system

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

[Photosensitivity and stability of freeze-dried and/or reconstituted measles vaccines (Biken CAM-70 strain)]

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Re-evaluation of the basic procedures involved in the storage of measles vaccine in public health units of the municipality of Niterói, State of Rio de Janeiro, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Room-temperature storage of medications labeled for refrigeration

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Validation of the shake test for detecting freeze damage to adsorbed vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Pathogen recognition by the innate immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Maturation of recombinant hepatitis B virus surface antigen particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Stabilization of measles virus for vaccine formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Characterization of the freeze sensitivity of a hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

A heat-stable hepatitis B vaccine formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Stabilization of vaccines: Lessons learned

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

US vaccine refrigeration guidelines: loose links in the cold chain

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Adjuvanted influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021

Immunogenicity of a locally produced hepatitis B vaccine with the birth dose stored outside the cold chain in rural Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FJ.BIOLOGICALS.2014.05.007

7 January 2021